| Stereochemistry | MIXED |
| Molecular Formula | C34H67O10P |
| Molecular Weight | 666.8635 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCC
InChI
InChIKey=BPHQZTVXXXJVHI-UHFFFAOYSA-N
InChI=1S/C34H67O10P/c1-3-5-7-9-11-13-15-17-19-21-23-25-33(37)41-29-32(30-43-45(39,40)42-28-31(36)27-35)44-34(38)26-24-22-20-18-16-14-12-10-8-6-4-2/h31-32,35-36H,3-30H2,1-2H3,(H,39,40)
| Molecular Formula | C34H67O10P |
| Molecular Weight | 666.8635 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | MIXED |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DIMYRISTOYLPHOSPHATIDYLGLYCEROL, DL- is a component of ABELCET® (Amphotericin B Lipid Complex Injection). It consists of amphotericin B complexed with two phospholipids in a 1:1 drug-to-lipid molar ratio. The two phospholipids, l-α-dimyristoylphosphatidylcholine and l-α-dimyristoylphosphatidylglycerol, are present in a 7:3 molar ratio. ABELCET® is indicated for the treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy. This is based on the open-label treatment of patients judged by their physicians to be intolerant to or failing conventional amphotericin B therapy.
Approval Year
Sample Use Guides
The recommended daily dosage for adults and children is 5 mg/kg given as a single infusion. ABELCET® should be administered by intravenous infusion at a rate of 2.5 mg/kg/h. If the infusion time exceeds 2 hours, mix the contents by shaking the infusion bag every 2 hours.
Route of Administration:
Intravenous
|
|
ACTIVE MOIETY |
|
Showing 1 to 1 of 1 entries